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Abstract
Background: Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and
Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients with
unresectable stage IIIB–IVM1c melanoma.
Methods: Patients were randomized 2:1 to receive intratumoral talimogene laherparepvec or subcutaneous
recombinant GM-CSF. In addition to overall survival (OS), durable response rate (DRR), objective response rate
(ORR), complete responses (CR), and safety are also reported. All final analyses are considered to be descriptive and
treatment responses were assessed by the investigators.
Results: Of 436 patients in the intent-to-treat population, 295 were allocated to talimogene laherparepvec and 141 to
GM-CSF. Median follow-up in the final OS analysis was 49months. Median OS was 23.3months (95% confidence interval
[CI], 19.5–29.6) and 18.9months (95% CI, 16.0–23.7) in the talimogene laherparepvec and GM-CSF arms, respectively
(unstratified hazard ratio, 0.79; 95% CI, 0.62–1.00; p = 0.0494 [descriptive]). DRR was 19.0 and 1.4% (unadjusted
odds ratio, 16.6; 95% CI, 4.0–69.2; p < 0.0001); ORR was 31.5 and 6.4%. Fifty (16.9%) and 1 (0.7%) patient in
the talimogene laherparepvec and GM-CSF arms, respectively, achieved CR. In talimogene laherparepvec-treated patients,
median time to CR was 8.6 months; median CR duration was not reached. Among patients with a CR, 88.5%
were estimated to survive at a 5-year landmark analysis. Talimogene laherparepvec efficacy was more pronounced in
stage IIIB–IVM1a melanoma as already described in the primary analysis. The safety reporting was consistent with the
primary OPTiM analysis.
Conclusions: In this final planned OPTiM analysis, talimogene laherparepvec continued to result in improved longer-term
efficacy versus GM-CSF and remained well tolerated. The final analysis also confirms that talimogene laherparepvec was
associated with durable CRs that were associated with prolonged survival.
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Background
Talimogene laherparepvec (T-VEC), a first-in-class viral
oncolytic immunotherapy [1], was approved in the United
States in 2015 for the local treatment of unresectable, cuta-
neous, subcutaneous and nodal lesions in patients with
melanoma recurrent after initial surgery [2], based on data
from OPTiM, a randomized phase III open-label trial [3–
5]. Intratumoral T-VEC significantly improved durable re-
sponse rate (DRR) versus subcutaneous GM-CSF; achieving
a durable response (DR; response lasting ≥6months) was
associated with clinical benefits such as overall survival
(OS) and quality of life [3]. In the primary analysis of OS
(secondary endpoint performed after 290 deaths; median
follow-up 44months), T-VEC showed a numerically re-
duced risk of death versus GM-CSF (median OS 18.9 vs.
23.3months; hazard ratio [HR] 0.79; 95% confidence inter-
val [CI], 0.62–1.00; P = 0.051) [4]. Exploratory analyses of
OPTiM revealed that the benefit of T-VEC versus GM-CSF
(in terms of DRR, objective response rate [ORR] and OS)
was more pronounced in patients with stage IIIB–IVM1a
disease than in later-stage metastatic disease [4, 5]. A tol-
erable safety profile for T-VEC, with a low rate of grade 3/
4 adverse events (AEs), was also observed [4]. In Europe,
T-VEC was approved in 2015 for unresectable, regionally
or distantly metastatic (stage IIIB–IVM1a) melanoma with
no bone, brain, lung or other visceral disease [6].
Here we report the final planned analysis of OS in
the OPTiM trial performed 3 years after the last patient
was randomized. Findings are described for the overall
intent-to-treat (ITT) population as well as in patients
with early metastatic disease (stage IIIB–IVM1a melan-
oma) included in the European label. Final analyses of
objective response, including exploratory analyses of
complete responders, are also discussed.
Methods
Patients
Eligibility criteria for the OPTiM trial have been described
previously [4]. Eligible patients were ≥ 18 years old and had
histologically confirmed, unresectable, bidimensionally
measurable stage IIIB/C/IV melanoma according to the 7th
edition AJCC staging system [7] with ≥1 cutaneous, sub-
cutaneous or nodal lesions that was suitable for direct or
ultrasound-guided injection. Other inclusion criteria in-
cluded an Eastern Cooperative Oncology Group (ECOG)
performance status of ≤1; serum lactate dehydrogenase
≤1.5 × upper limit of normal; ≤3 visceral lesions (excluding
lung or nodal lesions associated with visceral organs) with
none > 3 cm; and adequate organ function. Further details
are provided in the Additional file 1.
Study design and treatment
OPTiM (ClinicalTrials.gov NCT00769704) enrolled sub-
jects at 64 sites in the United States, the United
Kingdom, Canada, and South Africa between 2009 and
2011. Patients were randomized in a 2:1 ratio to receive
intratumoral T-VEC (at the approved dose [6]) or subcuta-
neous recombinant GM-CSF [4] (see Additional file 1).
Treatment continued for 6months regardless of the occur-
rence of progressive disease (unless alternative therapy was
clinically indicated). After 6months, treatment was contin-
ued until clinically relevant disease progression, intolerabil-
ity, consent withdrawal, complete remission, lack of
response by 12months or (T-VEC arm only) disappearance
of injectable lesions. Patients with stable or responding dis-
ease at 12months could continue treatment for 6 additional
months. Data cut-off for this final analysis of OPTiM was 5
September 2014.
Assessments and endpoints
Efficacy
Efficacy assessments reported here include analysis of
DRR, ORR, disease control rate (DCR) and OS using the
final OPTiM data set.
Clinical response was evaluated using the modified
World Health Organization criteria [8], as previously de-
scribed [4]. For the primary OPTiM analysis, patients with
an ORR (complete response [CR] or partial response [PR])
per investigator were evaluated by a blinded endpoint-
assessment committee [5]. After the primary analysis, only
response assessments per investigator were collected (and
are reported herein). DRR was defined as the rate of CR
or PR lasting continuously for ≥6months and onset within
≤12months of randomization. DCR was the proportion of
patients with CR, PR or stable disease.
An analysis of complete responders in the T-VEC arm
was conducted, including the time to achieve CR, the dur-
ation of CR once achieved and factors predictive of CR.
Analyses also evaluated associations between CR and OS,
CR and recurrence-free survival (RFS; date of CR to the
date of recurrence, death due to disease progression, or ini-
tiation of new anti-melanoma therapy after achieving CR)
and CR and treatment-free interval (TFI, time from the last
dose of study therapy to first dose of subsequent therapy or
censoring in the absence thereof at end of follow-up).
OS was defined as the time from random assignment
to death from any cause. Subgroup analyses were per-
formed to investigate the relative effects of treatment on
OS according to key covariates, including age, sex, dis-
ease stage, tumor burden, ECOG performance status,
and line of therapy.
Safety
Safety was evaluated from enrollment up to the data
cut-off for the final analysis using National Cancer
Institute Common Terminology Criteria for AEs (CTCAE)
version 3.0.
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Statistical analyses
Sample size was determined as described previously [4].
All efficacy analyses reported here are descriptive, as mul-
tiple comparisons were not controlled for. Final analysis
of DRR was conducted using a 2-sided unadjusted Fisher
exact test. Univariate and multivariate analyses (including
a logistic regression model) were conducted to identify in-
dependent factors associated with achieving CR. The final
descriptive analysis of OS was planned to occur 3 years
after the last randomization in OPTiM, and used an un-
adjusted log-rank test and a Cox proportional hazard
model to estimate the unstratified HR for treatment effect.
Five-year survival in the T-VEC arm was estimated using
the Kaplan-Meier method. Exploratory subgroup analyses
of OS by key covariates was carried out using the Gail and
Simon quantitative interaction test. Full details of the stat-
istical analyses can be found in the Additional file 1.
Results
Patients
Of the 436 patients in the ITT population, 295 (68%)
were allocated to receive T-VEC and 141 (32%) to GM-
CSF. Baseline characteristics, which have been previ-
ously reported [4], were generally well balanced between
treatment arms (see Additional file 1). Median (range)
duration of treatment was 23.1 weeks (0.1–176.7) in the
T-VEC arm and 10.0 weeks (0.6–120.0) in the GM-CSF
arm. Median follow-up (time from random assignment
to analysis) in the final analysis of OS was 49months.
Efficacy in the final OPTiM analysis dataset
Intent-to treat population (stage IIIB–IVM1c melanoma)
DRR was higher with T-VEC than GM-CSF: 57 (19.3%)
and 2 (1.4%) patients, respectively, experienced a durable
response per investigator assessment (unadjusted odds
ratio, 16.6; 95% CI, 4.0–69.2; p < 0.0001). ORR was also
higher with T-VEC (31.5%; 95% CI, 26.3–37.2) than GM-
CSF (6.4%; 95% CI, 3.0–11.8; Table 1). Overall, 50
(16.9%) and 1 (0.7%) patients in the T-VEC and GM-
CSF arms, respectively, achieved CR, while 43 (14.6%)
and 8 (5.7%) achieved PR (Table 1). Figure 1 illustrates
response duration. The DCR was 76.3% versus 56.7%
with T-VEC and GM-CSF, respectively (Table 1).
Median time to CR in T-VEC-treated patients was 8.6
months (range, 2.1–42.3; Fig. 2a). Eighteen months after
CR was achieved, the probability of remaining in CR was
78% (Fig. 2b). Compared with patients not achieving a
CR before a landmark time of 9 months, achieving a CR
was associated with an improvement in OS (Fig. 2c) and
TFI (Fig. 2d). Among patients with a CR, median OS
was not reached, with 88.5% (74–95) estimated to sur-
vive at a landmark analysis of 5 years. Overall, 72% of pa-
tients who achieved a CR were free from recurrence of
melanoma 3 years after achieving a CR (Fig. 2e). Table 2
summarises baseline demographics and disease charac-
teristics in T-VEC-treated patients achieving CR. Follow-
ing adjustment for potential confounding factors using
multivariate analysis, achievement of CR with T-VEC
was significantly associated with an earlier stage of meta-
static disease (Stage IIIB-IVM1a) and a baseline tumor
burden of < 14.5 cm2 (Fig. 2f ).
After five more months of follow-up versus the primary
analysis of OS [4], one additional survival event occurred.
Median OS was 23.3months (95% CI, 19.5–29.6) with T-
VEC and 18.9months (95% CI, 16.0–23.7) with GM-CSF
(Fig. 3a). Reduction in the risk of death was 21% with T-
VEC versus GM-CSF (unstratified HR, 0.79 [95% CI,
0.62–1.00]; P = 0.0494 [descriptive]). Estimated 5-year sur-
vival in the T-VEC arm was 33.4% (Table 1). Subgroup
analyses that were performed to investigate the relative ef-
fects of treatment across several key covariates for OS are
shown in Fig. 3e. When the 18 patients who did not re-
ceive allocated treatment were excluded (T-VEC arm, n =
4; GM-CSF arm, n = 14), median OS in the final analysis
dataset was 24.5 versus 18.9months for T-VEC versus
GM-CSF (HR, 0.78; P = 0.0439 [descriptive]; Fig. 3f).
According to an ad-hoc sensitivity analysis for OS ac-
counting for subsequent systemic anti-cancer treatment
(including ipilimumab, vemurafenib, dabrafenib, trameti-
nib or an anti-PD-1), there was a 27% reduction in the
risk of death for T-VEC versus GM-CSF (unadjusted
HR, 0.73; 95% Cl, 0.59–0.92; P = 0.0069 [descriptive]).
Stage IIIB–IVM1a disease
Effects of T-VEC on DRR, ORR, CR and DCR were
more pronounced in stage IIIB–IVM1a melanoma
(28.8% DRR, 46.0% ORR and 79.1% DCR) than in more
advanced disease (Table 1). Overall, 46/50 (92%) CRs oc-
curred in stage IIIB–IVM1a melanoma (Tables 1 and 2).
In T-VEC-treated patients, the CR rate in stage IIIB–
IVM1a disease was 28.2% (46/163) and the median time
to CR was 8.5 months (range, 2.1–42.3).
Effects of T-VEC on OS were particularly pronounced
versus GM-CSF among patients with stage IIIB/C (HR,
0.48, P < 0.05 [descriptive]; Fig. 3b) and stage IIIB–
IVM1a disease (HR, 0.56; 95% CI, 0.40–0.79; P < 0.001
[descriptive]; Fig. 3c) versus the ITT population includ-
ing in stage IVM1b/c disease (Fig. 3d). Estimated 5-year
survival with T-VEC was 48.9% (95% CI, 40.6–56.7) in
stage IIIB–IVM1a melanoma versus 15.1% (95% CI, 9.3–
22.2) in stage IVM1b/c disease.
Safety
The most common AEs were fatigue, chills, pyrexia, nau-
sea and influenza-like illness (Additional file 1: Table S1).
The incidence of these was highest during the first 3 cycles
and subsequently decreased (Additional file 1: Figure S1).
Most AEs lasted 2–4 days. Treatment-related grade 3/4
Andtbacka et al. Journal for ImmunoTherapy of Cancer           (2019) 7:145 Page 3 of 11
Table 1 Efficacy outcomes in final analysis data set of OPTiM
Talimogene
laherparepvec
(n = 295)
GM-CSF
(n = 141)
Descriptive
P-valuea
Difference
% 95% CIb
Response per investigator assessment in the intent-to-treat population (Stage IIIB–IVM1c disease)
DRR, n (%) 57 (19.3) 2 (1.4) < 0.0001 17.9 12.0–23.1
CR, n (%) 50 (16.9) 1 (0.7) – – –
PR, n (%) 43 (14.6) 8 (5.7) – – –
ORR, % (95% CI)b 31.5 (26.3–37.2) 6.4 (3.0–11.8) < 0.0001 25.1 17.4–31.7
SD, n (%) 132 (44.7) 71 (50.4) – – –
DCR, n (%) 225 (76.3) 80 (56.7) – 19.5 9.7–29.3
Progressive disease, n (%) 62 (21.0) 42 (29.8) – – –
Not assessed, n (%) 8 (2.7) 19 (13.5) – – –
Estimated OS probability in the intent-to-treat population (Stage IIIB–IVM1c disease), % (95% CI)
At 12 months 73.7 (68.3–78.4) 69.1 (60.6–76.2) – 4.6 −4.7–13.8
At 24months 49.8 (44.0–55.4) 40.3 (32.0–48.4) – 9.5 −0.5–19.6
At 36months 38.9 (33.3–44.4) 30.4 (22.9–38.3) – 8.4 −1.2–18.0
At 48months 34.5 (28.9–40.1) 23.9 (16.8–31.7) – 10.6 1.2–20.0
At 60months 33.4 (27.7–39.2) NE – NE NE
DRR, ORR, CR and DCR per investigator assessment according to disease stage
DRR, n/N (%)
IIIB/C 29/88 (33.0) 0/43 (0) < 0.0001 33.0 19.1–43.9
IVM1a 18/75 (24.0) 0/43 (0) 0.0003 24.0 10.5–35.5
IIIB–IVM1a 47/163 (28.8) 0/86 (0) < 0.0001 28.8 20.3–36.5
IVM1b 4/64 (6.3) 1/26 (3.8) 1.0000 2.4 −15.8–12.8
IVM1c 6/67 (9.0) 1/29 (3.4) 0.6710 5.5 −11.5–16.2
ORR, n/N (%)
IIIB/C 46/88 (52.3) 2/43 (4.7) < 0.0001 47.6 31.1–59.0
IVM1a 29/75 (38.7) 2/43 (4.7) < 0.0001 34.0 17.6–46.6
IIIB–IVM1a 75/163 (46.0) 4/86 (4.7) < 0.0001 41.4 30.6–49.9
IVM1b 9/64 (14.1) 2/26 (7.7) 0.5002 6.4 −13.8–19.5
IVM1c 9/67 (13.4) 3/29 (10.3) 1.0000 3.1 −16.3–16.5
CR, n/N (%)
IIIB/C 31/88 (35.2) 0/43 (0) – – –
IVM1a 15/75 (20.0) 1/43 (2.3) – – –
IIIB–IVM1a 46/163 (28.2) 1/86 (1.2) – – –
IVM1b 2/64 (3.1) 0/26 (0) – – –
IVM1c 2/67 (3.0) 0/29 (0) – – –
PR, n/N (%)
IIIB/C 15/88 (17.0) 2/43 (4.7) – – –
IVM1a 14/75 (18.9) 1/43 (2.3) – – –
IIIB–IVM1a 29/163 (17.8) 3/86 (3.5) – – –
IVM1b 7/64 (10.9) 2/26 (7.7) – – –
IVM1c 7/67 (10.4) 3/29 (10.3) – – –
DCR, n/N (%)
IIIB/C 75/88 (85.2) 23/43 (53.5) – 31.7 13.9–48.6
IVM1a 54/75 (72.0) 24/43 (55.8) – 16.2 −2.7–34.6
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AEs occurred in 33 (11.3%) T-VEC-treated patients and 6
(4.7%) GM-CSF-treated patients. The only grade 3/4 AE
occurring in ≥2% of T-VEC-treated patients was cellulitis
(2.1%) (Additional file 1: Table S1).
Immune-related AEs were reported in 24/295 T-VEC-
treated patients. Vitiligo was the most frequently re-
ported immune-related AE, occurring in 18 (6.2%) T-
VEC-treated patients (and one (0.8%) GM-CSF-treated
patient). All vitiligo events were grade 1/2. Median time
to vitiligo onset in the T-VEC arm was 22 weeks (inter-
quartile range, 9–36). No grade 4 immune-related AEs
were reported. Four grade 3 immune-related AEs were
observed: glomerulonephritis/renal failure (patient with
history of partial nephrectomy due to renal cell carcin-
oma and streptococcal injection site cellulitis), lupus
vasculitis, pneumonitis (patient with a history of ulcera-
tive colitis) and psoriasis (patient with psoriasis history).
The Additional file 1 provides further safety information.
Discussion
OPTiM was the first phase 3 trial to demonstrate a clinical
benefit with an oncolytic immunotherapy in any cancer
and the largest randomized controlled trial investigating a
therapeutic in unresectable stage IIIB/C melanoma. Fol-
lowing the previously reported analysis of the primary
endpoint of DRR [4], patients continued follow-up so that
a planned final analysis of OS could be performed 3 years
after randomization, as reported here. With 49months of
follow-up, median OS for T-VEC and GM-CSF was in line
with the primary analysis [4], and was 4.4 months longer
Table 1 Efficacy outcomes in final analysis data set of OPTiM (Continued)
Talimogene
laherparepvec
(n = 295)
GM-CSF
(n = 141)
Descriptive
P-valuea
Difference
% 95% CIb
IIIB–IVM1a 129/163 (79.1) 47/86 (54.7) – 24.5 11.5–37.0
IVM1b 50/64 (78.1) 16/26 (61.5) – 16.6 −4.9–39.3
IVM1c 46/67 (68.7) 17/29 (58.6) – 10.0 −11.4–32.2
aP-values calculated using Fisher’s Exact Test
bThe Clopper-Pearson method was used to calculate exact CIs for binary endpoints. Wilson’s score method with continuity correction was used to calculate an
approximate CI for between-group differences in binary rates
CI confidence interval, CR complete response, DCR disease control rate, DRR durable response rate, GM-CSF granulocyte-macrophage colony-stimulating factor, NE
not estimable, ORR overall response rate, OS overall survival, PR partial response
Fig. 1 Duration of response for all patients with response per investigator assessment. Duration of response is defined as the longest individual
period from entering response (PR or CR) to the first documented evidence of the patient no longer meeting the criteria for being in response or
death, whichever is earlier. CR, complete response; GM-CSF, granulocyte-macrophage colony-stimulating factor; PR, partial response
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in patients receiving T-VEC than GM-CSF (reduction in
the relative risk of death versus GM-CSF: 21%; P = 0.0494)
[4]. Overall, estimated 5-year survival for the T-VEC arm
was 33.4%. In accordance with the primary OPTiM analysis
[4], the effects of T-VEC on OS were more pronounced in
patients with early metastatic melanoma (stage IIIB–
IVM1a), with an estimated 5-year survival of 48.9%.
The final OPTiM data set was further analysed in the
17% of patients treated with T-VEC who achieved a CR.
Once achieved, CRs were durable; the median duration
(See figure on previous page.)
Fig. 2 Analyses of CR in stage IIIB–IVM1c melanoma. a Time to achieve CR in patients treated with talimogene laherparepvec; b Duration of CR in patients
treated with talimogene laherparepvec; c Kaplan-Meier plot of OS in patients who achieved a CR versus patients who did not achieve a CR prior to a
landmark time of 9months; d Kaplan-Meier plot of TFI in patients who achieved a CR versus patients who did not achieve a CR prior to a landmark time
of 9months; e RFS after achieving a CR with talimogene laherparepvec; f Factors associated with achieving CR with talimogene laherparepvecf. aCR
duration was defined as the interval from the initial date of CR to the first response of non-CR. Ongoing CRs were censored at the date with a CR. The
longest interval was utilized due to multiple CR intervals. Median follow-up for CR duration = 7months (range < 1 to 20months). bFor landmark analyses,
OS was calculated from the landmark time of 9months after randomization to death. Unadjusted hazard ratios and log-rank P-values are shown. cTFI was
defined as the interval from the last dose of study therapy and the first dose of systemic therapy categorized as chemotherapy/targeted agent or
immunotherapy. The TFI analysis was limited to treated patients with tumor assessments ≥9months. Unadjusted hazard ratios (HR) and log-rank P-values
are shown. dRFS after achieving a CR was calculated from date of CR to date of recurrence, death due to disease progression, or start of new anti-
melanoma therapy. Median follow-up for RFS = 31months (range 1 to 53months). e14.5 cm2 was the median tumor burden. fPatients treated with
talimogene laherparepvec who achieved CR (n = 50) versus those who did not (n = 245) using logistic regression models. AJCC, American Joint
Committee on Cancer; CI, confidence interval; CR, complete response; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; ITT, intent-to-treat; NE,
not evaluable; OR, odds ratio; OS, overall survival; RFS, recurrence-free survival; TFI, treatment-free interval
Table 2 Characteristics of patients treated with talimogene laherparepvec in OPTiM by complete response and partial response (per
investigator assessment)a
Characteristic Complete response (n = 50) Partial response (n = 43)
Median (IQR) age, years 70 (60–78) 63 (53–77)
Female 20 (40) 21 (49)
ECOG performance status = 0 42 (84) 31 (72)
AJCC stage
IIIB/C 31 (62) 15 (35)
IVM1a 15 (30) 14 (33)
IIIB–IVM1a 46 (92) 29 (67)
IVM1b 2 (4) 7 (16)
IVM1c 2 (4) 7 (16)
In-transit or distant skin metastases
IIIB–IVM1a 42 (84) 20 (47)
IIIB–IVM1c 44 (88) 26 (60)
Elevated LDH (>ULN) 0 0
Line of treatment
1st 33 (66) 27 (63)
≥ 2nd 17 (34) 16 (37)
Median baseline tumor burden (range), cm2 4.6 (0.3–38.3) 10.9 (0.6–280.6)
BRAF status
Mutation 5 (10) 9 (21)
Wild type 5 (10) 9 (21)
Unknown/missing 40 (80) 25 (58)
HSV-1 seropositive at baseline 32 (64) 28 (65)
Data presented are number (%) of patients, unless otherwise indicated
aAmong 295 patients randomized to talimogene laherparepvec, 291 received treatment and 287 were evaluable for response assessment per
investigator assessment
AJCC American Joint Committee on Cancer, ECOG Eastern Cooperative Oncology Group, HSV herpes simplex virus, IQR interquartile range, LDH lactate
dehydrogenase, ULN upper limit of normal
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was not reached over a median follow-up period of more
than 4 years. Additionally, median OS in these patients
was not reached and approximately 90% were estimated
to be alive at 5 years. Similar to T-VEC, prolonged CR
duration (once achieved) and association with survival has
been reported in checkpoint inhibitor (CPI) trials [9, 10].
Our analyses showed that early metastatic melanoma
(stage IIIB–IVM1a) and lower tumor burden (< 14.5 cm2)
were independent predictors of achieving a CR. These
findings indicate that earlier commencement of an effect-
ive treatment is important for resolution of melanoma
and, in turn, long-term survival. Recent analyses also dem-
onstrated that less advanced disease and lower tumor bur-
den are associated with achieving a CR with CPIs [9, 10].
The median time to achieve CR among T-VEC-treated pa-
tients was 8.6 months. Prior analyses showed that almost
half of patients responding to T-VEC monotherapy exhibit
progression prior to the response [5, 11]. Although pro-
gression prior to response prolongs the time it takes to
achieve a response, it does not impact the duration of a re-
sponse once achieved [11]. Hence, if there are injectable
lesion(s) remaining, T-VEC should be continued for ≥6
months unless the patient is not benefitting from treat-
ment or another treatment is required.
As previously demonstrated [4] and confirmed here, T-
VEC exhibits a tolerable safety profile with a low rate of
grade 3/4 AEs. The incidence of treatment-related grade
3/4 AEs with T-VEC in OPTiM was similar to that re-
ported for anti-programmed cell death protein-1/ligand 1
monotherapy [12–16] and lower than that observed with
anti-cytotoxic T-lymphocyte-associated protein-4 mono-
therapy [14, 17]. However, T-VEC is not associated with
the same pattern of serious immune-related AEs reported
with CPI therapy, such as thyroid dysfunction, hypophysi-
tis, adrenal insufficiency and autoimmune hepatitis [16,
18–20]. It can take months to see an improvement in
these AEs and some may never resolve [16, 18–20].
Interest in the use of T-VEC combined with systemic
immunotherapy has arisen due its favorable safety pro-
file, proven efficacy as monotherapy, and potentially
complementary mode of action, with an ability to acti-
vate a CD8 + -dependent systemic immune response
[21]. To date, T-VEC combined with CPIs in melanoma
has shown improved efficacy versus CPIs alone without
notable additional safety concerns [22–25]. A phase III
trial of T-VEC/placebo plus pembrolizumab is under-
way in unresectable stage IIIB–IVM1c melanoma
(MASTERKEY 265; NCT02263508).
Even if the final OS analysis was planned, a limitation
is that all final subgroup analyses were descriptive, and
some were post-hoc and exploratory. Additionally, after
the primary OPTiM analysis, only response assessments
per investigator were collected. In contrast, in the pri-
mary analysis of OPTiM, the investigator-reported ORRs
(CR + PR) were independently evaluated by a blinded
endpoint-assessment committee. Nevertheless, the final
analyses presented here provide important new practical
insights into the use of T-VEC in patients with unresect-
able stage III–IV melanoma.
In conclusion, as well as demonstrating a longer-term
effect on survival, this analysis confirms that T-VEC re-
sulted in high CR rates, most notably in patients with
early metastatic melanoma (stage IIIB–IVM1a). Once
achieved, CRs were durable and associated with pro-
longed survival. The favorable clinical outcomes ob-
served in some patients treated with T-VEC, along with
its good safety profile, support continued efforts to fur-
ther define its future role in melanoma as a combination
partner with immunotherapy.
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